Abstract
Background: Antidepressant medication is a major cornerstone in treatment of mood and anxiety disorders. Numerous substances are available on the market; however, only 60% of treated patients show sufficient response to medication and side effects are common. Lengthy trials are not uncommon until the optimized drug and dose is found and unfortunately, no valid predictors to match the ‘right’ drug to the ‘right’ patient exist nowadays. Genetic factors are thought to be involved as evidenced by numerous pharmacogenetic studies. This comprehensive review summarizes the most interesting findings and discusses clinical implications of pharmacogenetic results.
Methods: We reviewed available literature on pharmacogenetics of antidepressant response and side effects until summer 2011 using the PubMed database.
Results: Promising findings exist for several variants in candidate genes involved in the pharmacokinetics or pharmacodynamics of antidepressants. These include association findings in the serotonin transporter gene (5-HTT), serotonin receptor genes, a gene coding an efflux pump in the blood-brain-barrier (ABCB1), and genes involved in the HPA axis. Promising candidate genes increasing risk for side effects include some of the genes associated with treatment response and cytochrome P450 genes.
Conclusion: A high number of studies on pharmacogenetics of antidepressants have been published during the past decades. However, contradictory results still limit clinical use of these findings. Future studies should include functional analyses and consider gene-gene and gene-environment interactions. This will aid in facilitating a future use of pharmacogenetics in clinical practice, likely leading to improved patient care.
Keywords: Pharmacogenetics, antidepressant, response, side-effects, polymorphism, 5-HTTLPR, ABCB1, serotonin, FKBP5, gene-environment interactions
Current Pharmaceutical Design
Title:Genetics and Personalized Medicine in Antidepressant Treatment
Volume: 18 Issue: 36
Author(s): Katarina Gvozdic, Eva J. Brandl, Danielle L. Taylor and Daniel J. Muller
Affiliation:
Keywords: Pharmacogenetics, antidepressant, response, side-effects, polymorphism, 5-HTTLPR, ABCB1, serotonin, FKBP5, gene-environment interactions
Abstract: Background: Antidepressant medication is a major cornerstone in treatment of mood and anxiety disorders. Numerous substances are available on the market; however, only 60% of treated patients show sufficient response to medication and side effects are common. Lengthy trials are not uncommon until the optimized drug and dose is found and unfortunately, no valid predictors to match the ‘right’ drug to the ‘right’ patient exist nowadays. Genetic factors are thought to be involved as evidenced by numerous pharmacogenetic studies. This comprehensive review summarizes the most interesting findings and discusses clinical implications of pharmacogenetic results.
Methods: We reviewed available literature on pharmacogenetics of antidepressant response and side effects until summer 2011 using the PubMed database.
Results: Promising findings exist for several variants in candidate genes involved in the pharmacokinetics or pharmacodynamics of antidepressants. These include association findings in the serotonin transporter gene (5-HTT), serotonin receptor genes, a gene coding an efflux pump in the blood-brain-barrier (ABCB1), and genes involved in the HPA axis. Promising candidate genes increasing risk for side effects include some of the genes associated with treatment response and cytochrome P450 genes.
Conclusion: A high number of studies on pharmacogenetics of antidepressants have been published during the past decades. However, contradictory results still limit clinical use of these findings. Future studies should include functional analyses and consider gene-gene and gene-environment interactions. This will aid in facilitating a future use of pharmacogenetics in clinical practice, likely leading to improved patient care.
Export Options
About this article
Cite this article as:
Gvozdic Katarina, J. Brandl Eva, L. Taylor Danielle and J. Muller Daniel, Genetics and Personalized Medicine in Antidepressant Treatment, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523617
DOI https://dx.doi.org/10.2174/138161212803523617 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Medicinal Chemistry Reviews - Online (Discontinued) Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Current Drug Abuse Reviews Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Current Topics in Medicinal Chemistry A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far
Current Drug Research Reviews Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Anticancer Drugs Targeting the Apoptotic Pathway
Medicinal Chemistry Reviews - Online (Discontinued) Dopexamine After Heart Surgery: An Uncommonly Used, Though Useful Inotropic Agent
Recent Patents on Cardiovascular Drug Discovery An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Antihypertensive Effect of Sesamin
Vascular Disease Prevention (Discontinued) Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Multidrug Transporters as Drug Targets
Current Drug Targets Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued)